Shareholders meeting

September 03, 2026 To, To, Listing/Compliance Department Listing/Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, Dalal Street, G-Block, Bandra-Kurla Complex, Mumbai – 400001 Bandra (E), Mumbai – 400051 BSE CODE – 543998 NSE Symbol: VALIANTLAB Dear Sir/Madam, Sub.: Notice of the 5th Annual General Meeting & Annual Report for the Financial Year 2025-26 Ref: Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Valiant Laboratories Limited (the “Company”) is pleased to share its Annual Report for the Financial Year 2025-26, together with the Notice convening the 5th Annual General Meeting (“AGM”). The AGM is scheduled to be held on Monday, September 28, 2026, at 11:30 a.m. (IST) through Video Conferencing / Other Audio Visual Means. Further, in accordance with the MCA and SEBI Circulars, the Notice of the AGM along with the Annual Report is sent only through electronic mode to those Members whose email addresses are registered with the Company/Depository Participants as on Friday, August 28, 2026. The Notice of 5th AGM of the Company along with Annual Report for the Financial Year 2025-26 is available on the website of the Company at the below web-link: https://www.valiantlabs.in/assets/images/investors/annual-report-2026.pdf We request you to take the same on record. Thanking you, Yours faithfully, For Valiant Laboratories Limited Akshay Gangurde Company Secretary & Compliance Officer Encl: As above www.valiantlabs.in | CIN: L24299MH2021PLC365904 Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (West), Mumbai - 400080. Corporate Office: 701-A, 7th Floor, Tower-B, Embassy 247, L.B.S. Road, Vikhroli (West), Mumbai-400083. T: 022-49717221/49712001/49717220 | E: investor@valiantlabs.in Annual Report 2025-26 Transforming Potential into Progress Transforming Contents Potential into 02-24 81-187 Progress Corporate Overview Financial Statements Who We Are 02 Standalone MD’s Message 04 Independent Auditors’ Report 81 Financial Highlights 06 Balance Sheet 90 Our Journey 08 Statement of Profit and Loss 91 Every journey of progress begins with That has been the story of Valiant Laboratories. For over four Geographic Footprint 10 Statement of Cash Flows 92 recognising potential and having the decades, we have steadily built on our strengths, expanding our Valiant Advanced Sciences Private Limited 11 expertise, refining our processes and investing in capabilities Standalone Statement of Changes in Equity 94 conviction to nurture it. What starts as Manufacturing 12 that prepare us for the future. Each milestone has strengthened Statement of Significant Accounting Policies, Supply Chain 16 Accounting Estimates and Judgements 95 an idea, an investment or a capability the foundation for the next, shaping a business that is more Environment 18 Notes Forming Part of Financial Statements 105 gradually evolves into something far resilient, agile and equipped to meet the evolving needs of the Social 19 pharmaceutical industry. Governance 20 greater through persistence, discipline During FY2025-26, this journey gathered fresh momentum. The Our Leadership Team 22 Consolidated and a clear sense of purpose. expansion of our manufacturing capacity, the commercialisation Corporate Information 24 Independent Auditors’ Report 136 of Valiant Advanced Sciences, deeper backward integration Balance Sheet 142 and sustained investments in quality, operational excellence Statement of Profit and Loss 143 and responsible business practices reflect our ability to convert 25-79 Statement of Cash Flows 144 opportunity into tangible outcomes. Consolidated Statement of Changes in Equity 146 Statutory Reports This is where Transforming Potential into Progress comes to Statement of Significant Accounting Policies, life. It is a journey shaped by purposeful choices, thoughtful Accounting Estimates and Judgements 147 investments and the pursuit of better ways of working. Every Notes Forming Part of Financial Statement 157 Management Discussion and Analysis 25 capability we build, every milestone we achieve and every Report of the Board of Directors 36 opportunity we unlock becomes part of a larger story, one that Report on the Corporate Governance 59 is steadily shaping a stronger Valiant Laboratories for the future. 188-244 Notice of AGM Notice 188 Forward-looking statement Some information in this report may contain forward-looking statements. We have based these statements on our current beliefs, expectations and intentions as to facts, actions and events that will or may occur in the future. Such statements generally are identified by futuristic words such as ‘believe’, ‘plan’, ‘anticipate’, To know more about the company, ‘continue’, ‘estimate’, ‘expect’, ‘may’, ‘will’ or other similar words. log on to https://valiantlabs.in These statements may include assumptions or basis underlying the futuristic statement. We have chosen these assumptions or basis in good faith, and we believe that they are reasonable in all material respects. However, we caution you that these statements might vary from actual results, and the differences between the results implied by the statements and actual results can be material, Scan the QR Code depending on the circumstances. to view the report online Corporate Overview Statutory Reports Financial Statements Annual Report 2025-26 02 03 Who We Are From Vision to Progress With over 45 years of manufacturing excellence, Valiant Laboratories Limited is a pharmaceutical company and one of India’s leading manufacturers of high-quality Active Pharmaceutical Ingredients (APIs), with a strong presence in the Paracetamol API segment. Our Performance at a Glance As part of the Aarti Group of Industries, we are built on a trusted legacy that traces back to 1980 with Bharat Chemicals, Progress in Perspective where we developed deep expertise in Para Nitro Phenol production. Guided by sustained investment in research, process innovation and technical expertise, we expanded into pharmaceuticals and established ourselves as a trusted manufacturer of Paracetamol. As healthcare needs evolve, we are enhancing our capabilities, advancing operational excellence and strengthening our readiness to capture new opportunities. Our Vision Valiant Laboratories aims to establish itself as the foremost supplier of bulk drugs, achieving leadership through: Embracing the most Implementing cost- efficient and adaptable effective and safe manufacturing Maintaining a Financial Highlights (Standalone) Consistently Prioritising customer processes supported practices and steadfast commitment delivering superior satisfaction through by cutting-edge methods to ensure to sustainability, H H H quality products continuous technological technologies operational excellence community 31,976 Lakhs 1,007 Lakhs 21,704 Lakhs responsibility and punctually and at advancement, ethical employee well-being Net Worth EBITDA Total Revenue competitive prices business practice, and innovative product development 555 Lakhs Our Mission Operational Highlights Valiant Laboratories is dedicated to diversifying into new chemistries and industries, increasing our market share and optimising operational efficiencies through the backward integration of our proposed facility. Commencement ISO 9001:2015 We are committed to expanding our footprint in foreign and regulated markets while delivering innovative solutions that address global of Commercial and GMP healthcare challenges. Production at VASPL Certified Upholding the highest standards of quality and ethical practices, we foster long-term partnerships and sustainable growth. Our mission is to pioneer advancements in pharmaceuticals, ensuring accessible and (November 2025) effective healthcare solutions worldwide. Corporate Overview Statutory Reports Financial Statements Annual Report 2025-26 04 05 MD’s Message Valiant Laboratori [Showing first 8,000 characters — download PDF for full document]